Loading provider…
Loading provider…
Internal Medicine Physician in San Francisco, CA
NPI: 1437117454Primary Practice Location
UCSF MEDICAL CENTER
1975 4th St, San Francisco, CA
Primary Employer
UCSF Medical Center
ucsfhealth.org
HQ Phone
Get MD Eric's Phone Numberphone_androidMobile
Get MD Eric's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1987 - 2026

American Board of Internal Medicine
Internal Medicine

National Board of Physicians and Surgeons
Internal Medicine

National Board of Physicians and Surgeons
Medical Oncology
Beth Israel Deaconess Medical Center
Residency • Internal Medicine
1985 - 1988
UCSF School of Medicine
medschool.ucsf.edu
Fellowship • Hematology and Medical Oncology
1988 - 1989
Cleveland Medical College, Homeopathic
case.edu
Medical School
Until 1985
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 136 | 220 |
| 2 | 99205New patient office or other outpatient visit, typically 60 minutes | 75 | 75 |
| 3 | J9217Leuprolide acetate (for depot suspension), 7.5 mg | 16 | 87 |
| 4 | 96402Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | 16 | 27 |
Authors: Philip Kantoff, Howard Scher, William Oh, Himisha Beltran, Mack Roach, Eleni Efstathiou, Christopher Evans, Brett Carver, Celestia Higano, Charles Drake
Journal: Eur Urol
Publication Date: 2020-01-27
Authors: Philip Kantoff, Matthew Galsky, Howard Scher
Journal: Clin Cancer Res
A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
Authors: Fairooz Kabbinavar, Nizar Tannir
Journal: BJU Int
Lead Sponsor: University of California, San Francisco
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Selinexor
Lead Sponsor: OHSU Knight Cancer Institute
Collaborators: Oregon Health and Science University, Astellas Pharma US, Inc.
Intervention / Treatment: DRUG: Enzalutamide
Lead Sponsor: OHSU Knight Cancer Institute
Collaborators: United States Department of Defense, Oregon Health and Science University
Intervention / Treatment: DRUG: Enzalutamide, OTHER: Laboratory Biomarker Analysis, OTHER: Cytology Specimen Collection Procedure